Template talk:Nuclear receptor modulators

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia
WikiProject iconPharmacology Redirect‑class
WikiProject iconThis redirect is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.
RedirectThis redirect does not require a rating on Wikipedia's content assessment scale.
WikiProject iconChemicals NA‑class
WikiProject iconThis redirect is within the scope of WikiProject Chemicals, a daughter project of WikiProject Chemistry, which aims to improve Wikipedia's coverage of chemicals. To participate, help improve this redirect or visit the project page for details on the project.
NAThis redirect does not require a rating on Wikipedia's content assessment scale.
WikiProject iconMedicine Redirect‑class
WikiProject iconThis redirect is within the scope of WikiProject Medicine. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.
RedirectThis redirect does not require a rating on Wikipedia's content assessment scale.
WikiProject iconMolecular Biology: MCB Redirect‑class
WikiProject iconThis redirect is within the scope of WikiProject Molecular Biology, a collaborative effort to improve the coverage of Molecular Biology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.
RedirectThis redirect does not require a rating on Wikipedia's content assessment scale.
Taskforce icon
This redirect is supported by the Molecular and Cell Biology task force.

Good job![edit]

Thanks for creating this useful template. A couple of questions though:

  • Is VDR in the right place? It is no more a steroid hormone than thyroid or retinoic acid.
  • Is the aim to keep entries alphabetical? This runs into difficulties with numbered compounds.
  • What about weak or partial agonists that "antagonize" the natural agonists?

Will look forward to additions to this. Jrfw51 (talk) 09:39, 20 August 2015 (UTC)[reply]